Authors

49 Financial Toxicity Among Patients With Breast Cancer During the COVID-19 Pandemic

Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies

Several lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.

Ra-223 Improves Outcomes in Prostate Cancer With Bone Metastases

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.

18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19

47 Effect of Postmastectomy Radiation Therapy on Outcomes for Implant-Based Reconstruction

In this retrospective cohort of 99 patients, PMRT-related post-reconstruction complications occurred in 25%, with chemotherapy receipt associated with significantly lower complication risk and no association found for BMI, cancer stage, or reconstruction type.

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study

Kira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

46 Improving Breast Cancer–Related Lymphedema and Upper Extremity Dysfunction: Why Multidisciplinary Care Matters

This narrative review synthesizes evidence on breast cancer–related lymphedema prevention and management, finding that surgical mitigation strategies and coordinated radiation planning within multidisciplinary pathways reduce BCRL risk and improve survivorship outcomes.

Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship

The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

Decisional Capacity Determination in Patients With Cancer

Experts discuss the process of assessing decision-making capacity in patients with cancer.

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

47 Effect of Postmastectomy Radiation Therapy on Outcomes for Implant-Based Reconstruction

In this retrospective cohort of 99 patients, PMRT-related post-reconstruction complications occurred in 25%, with chemotherapy receipt associated with significantly lower complication risk and no association found for BMI, cancer stage, or reconstruction type.

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1

Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.

75 Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast

Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017

Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.

How Radiologists Could Use Cryoablation to Put Cancer Pain on Ice

J. David Prologo, MD, FSIR, ABOM-D, an interventional radiologist at Emory Healthcare, details how cryoablation can be used by radiologists to manage pain in patients with cancer.

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review

Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.

27 Transfusion and Anemia Management Strategies in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Literature Review

This literature review of 10 studies found that anemia is common during NAC, with restrictive transfusion thresholds and intravenous iron supplementation showing favorable safety profiles, while ESA use and blood transfusions raised concerns about oncologic outcomes.

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.

64 A Phase I/II Study of Pembrolizumab and Anti-CD3 x Anti-HER2 Armed Activated T-Cells in Metastatic Breast Cancer

This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.